Hengbing Wang1, Qing Cao, Arkadiusz Z Dudek. 1. Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA.
Abstract
BACKGROUND: This single-arm, phase II study was designed to determine the efficacy and safety of panobinostat and bortezomib in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Patients had to have a histological diagnosis of pancreatic cancer and progression on a standard gemcitabine-based therapy. Treatment cycles consisted of 21 days, with bortezomib given twice weekly at 1.3 mg/m(2) and panobinostat three times weekly at 20 mg during the first two weeks, followed by a 9-day rest period. RESULTS: Seven patients (3 female, 4 male) were treated with at least one cycle, but the study was suspended after the enrollment of these patients because of a complete lack of treatment responses and early treatment-related toxicity. Median progression-free survival was 2.1 months (95% Confidence interval: 1.7-2.3 months). The most common grade 3 or 4 adverse events were thrombocytopenia (57%) and diarrhea (29%). CONCLUSION: Treatment of advanced pancreatic cancer with bortezomib in combination with panobinostat is not supported by our clinical study.
BACKGROUND: This single-arm, phase II study was designed to determine the efficacy and safety of panobinostat and bortezomib in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Patients had to have a histological diagnosis of pancreatic cancer and progression on a standard gemcitabine-based therapy. Treatment cycles consisted of 21 days, with bortezomib given twice weekly at 1.3 mg/m(2) and panobinostat three times weekly at 20 mg during the first two weeks, followed by a 9-day rest period. RESULTS: Seven patients (3 female, 4 male) were treated with at least one cycle, but the study was suspended after the enrollment of these patients because of a complete lack of treatment responses and early treatment-related toxicity. Median progression-free survival was 2.1 months (95% Confidence interval: 1.7-2.3 months). The most common grade 3 or 4 adverse events were thrombocytopenia (57%) and diarrhea (29%). CONCLUSION: Treatment of advanced pancreatic cancer with bortezomib in combination with panobinostat is not supported by our clinical study.
Authors: Carina Fischer; Katharina Leithner; Christoph Wohlkoenig; Franz Quehenberger; Alexandra Bertsch; Andrea Olschewski; Horst Olschewski; Andelko Hrzenjak Journal: Mol Cancer Date: 2015-01-21 Impact factor: 27.401